DGKH and cancer: We reviewed the recent work by Loh et al., which identified diacylglycerol kinase eta (DGKH) as a pivotal driver of cancer stemness/self-renewal and resistance to tyrosine-kinase inhibitors (TKIs) in hepatocellular carcinoma (HCC).1